GSK reported second-quarter 2026 core earnings of $1.36 per American depositary share, beating the Zacks Consensus Estimate of $1.27, and announced a three-year Accelerate Growth program targeting £1.9 billion in annualized cost savings by 2029. Quarterly revenues rose 5% at constant exchange rates to $11.28 billion, also surpassing the consensus of $10.79 billion, driven by higher sales in HIV, Oncology, Respiratory medicines and Vaccines. Specialty Medicines sales increased 14%, led by a 10% rise in HIV sales and a 17% jump in Oncology sales, while Vaccines sales grew 8% and General Medicines sales declined 9%. The company reaffirmed its 2026 revenue growth guidance of 3-5% and now expects core operating profit and core EPS to grow 7-9%, at the upper half of the range. Management plans to reinvest the cost savings into R&D, with more than 20 phase III studies now expected in 2026, and reiterated its 2031 sales target of more than £40 billion.
GSK plcGSK beat Q2 earnings and revenue estimates and announced a £1.9 billion cost-saving plan
Harmony Biosciences Holdings
Johnson & Johnson
Liquidia Technologies Inc